Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma Diagnosis Clear all
Completed Not applicable Interventional Results available

Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived

NCT03469297
View directory record Official record
Conditions
Glaucoma
Interventions
Brown Glaucoma Implant
Device
Lead sponsor
MicroOptx
Industry
Eligibility
22 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Bloomington, Minnesota • Dayton, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

NCT00047541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Jul 23, 2026, 6:29 PM EDT
Completed No phase listed Observational Results available

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

NCT01836042
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 23, 2026, 6:29 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma

NCT02014597
View directory record Official record
Conditions
Glaucoma
Interventions
HOCD
Device
Lead sponsor
Benjamin Frankfort, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Jul 23, 2026, 6:29 PM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT01830140
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01%, Bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Artesia, California • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jul 23, 2026, 6:29 PM EDT
Terminated Not applicable Interventional

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

NCT04769453
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro
Device
Lead sponsor
Nova Eye, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 23, 2026, 6:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?

NCT00626847
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 23, 2026, 6:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

NCT02247804
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Glendale, California • Irvine, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 23, 2026, 6:29 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

NCT01345448
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine, Placebo Lotion
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

NCT01001195
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Jul 23, 2026, 6:29 PM EDT
Recruiting Phase 2 Interventional

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 6:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care

NCT04994457
View directory record Official record
Conditions
Glaucoma
Interventions
Virtual Reality Visual Field, Standard Automated Perimetry
Device · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 90 Years
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Jul 23, 2026, 6:29 PM EDT
Completed No phase listed Observational

The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure

NCT02165631
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome, Pseudoexfoliation Glaucoma
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jul 23, 2026, 6:29 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Eye Drop Application Monitor, Pilot Study

NCT02639845
View directory record Official record
Conditions
Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions
Not listed
Lead sponsor
Alexander Eaton
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Jul 23, 2026, 6:29 PM EDT
Completed No phase listed Observational

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

NCT00001161
View directory record Official record
Conditions
Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

NCT03519386
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 6:29 PM EDT
Recruiting Phase 4 Interventional

Travoprost Intraocular Implant + iStent Infinite

NCT06066645
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Travoprost Intraocular Implant, iStent infinite, Sham procedure
Drug · Device · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 23, 2026, 6:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Innovations in Glaucoma Study

NCT00221897
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Myopia
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 23, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jul 23, 2026, 6:29 PM EDT
Completed No phase listed Observational

A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure

NCT00706056
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 101 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 23, 2026, 6:29 PM EDT